BAT's 2022 Performance Report: Strong Growth in New Categories

Feb.10.2023
BAT's 2022 Performance Report: Strong Growth in New Categories
BAT's 2022 report shows total revenue of £27.655 billion, with 40.9% growth in new categories, including a 54.9% increase in e-cigarette sales.

On February 9th, British American Tobacco (BAT) released their 2022 financial report, revealing a total revenue of £27.655 billion, a year-on-year growth of 7.7%, as well as an operating profit of £10.523 billion, a growth of 2.8%. The report indicated that global cigarette growth remained consistent with the previous year, with the US market seeing a 10% increase. Additionally, the new category business, which includes electronic cigarettes, heated tobacco products, and nicotine pouches, generated £2.9 billion in revenue, representing a 40.9% year-on-year increase.


Annual report data | Image source: official websites of Baidu, Alibaba, and Tencent (BAT)


The development of a new category has surged, with a growth of 54.9% in the electronic cigarette business.


A new category sector consisting of e-cigarette products, heated tobacco products, and nicotine pouches contributed £2.9 billion to revenue in 2022, resulting in a 2.3% increase in total revenue.


The electronic cigarette business reached £1.436 billion, experiencing a growth of 54.9%; tobacco heating products accounted for £1.06 billion, a growth of 24.3%; while the chewing tobacco business generated £0.04 billion, with a growth of 45.3%.


New classification of business data | Image source: Official websites of BAT (Baidu, Alibaba, Tencent)


BAT CEO Jack Bowles has stated that the "New Category" division is expected to achieve profitability in 2024, a year earlier than previously anticipated.


According to Jack Bowles, "Our new category business has achieved strong growth in sales, revenue, and market share, and has become a significant contributor to the group's performance. In 2022, we have invested over £2 billion in the new category to drive long-term sustainable growth, while making excellent progress in reducing operating losses by 62%.


BAT forecasts that by 2025, revenue from its "new categories" division will reach £5 billion.


The US market is significantly outperforming with electronic cigarette business growth of over 60%.


In its financial report, BAT divided its primary regions into the United States, Europe (excluding Russia and Belarus), Latin America, Sub-Saharan Africa (AmSSA), and the Asia-Pacific and Middle East regions.


Image Source: Compiled by 2FIRSTS


In the United States market, the revenue for 2022 is projected to be 12.639 billion pounds, representing a year-on-year growth of 8.1%. The new categories of electronic cigarettes, THP, and nicotine pouches are expected to generate 0.949 billion pounds with electronic cigarettes alone contributing 0.913 billion pounds, representing an increase of 62.9%.


Europe's tobacco industry saw a 5.7% increase, valued at £6.346 billion (excluding Russia and Belarus). The new category, consisting of e-cigarettes, tobacco-heating products (THP), and nicotine pouches, accounted for £1.171 billion. E-cigarettes saw a significant increase of 37.9%, with revenues of £286 million. THP accounted for £537 million, and nicotine pouches for £348 million.


The Americas and sub-Saharan Africa (AmSSA) saw a growth of 10.6% to reach 4.203 billion pounds. A new category (electronic cigarettes, THPs, and nicotine pouches) reached 219 million pounds, with electronic cigarettes contributing 218 million pounds and a year-on-year growth of 55.1%.


The Asia-Pacific and Middle East regions earned £4.467 billion, marking a 6.6% growth. In the new category, £555 million was generated, with the e-cigarette business contributing £19 million and experiencing a growth of 4.3%, while the THP business contributed £523 million.


As a result of factors such as the Russian market and the closure of multiple factories, the operating profit margin has decreased by 1.7%.


In 2022, the operating profit of BAT increased by 2.8% year on year to reach 10.523 billion pounds, while the operating profit margin decreased by 1.7% year on year to 38.1%. The reason for this is as follows:


The growth of foreign exchange by 7.6% offset the impact of some one-time projects, thanks to the relative weakness of the pound against BAT's operating currency (especially the US dollar) and reduced losses in a new category.


British American Tobacco (BAT) has decided to divest its business operations in Russia and Belarus. These businesses have been listed as assets for sale, with an estimated recoverable value. However, the value has been reduced by £612 million due to impairment.


The restructuring plan for the group, Quantum, which includes withdrawing from Egypt and closing factories in the United States, Singapore, and Switzerland, has a total cost of £771 million.


The company has been accused of violating Nigeria's Competition and Consumer Protection Act and the National Tobacco Control Act, and is under investigation by the US Department of Justice (DOJ) and the Office of Foreign Assets Control (OFAC) of the US Treasury Department for alleged historical breach of sanctions, with costs amounting to £450 million.


Reference:


New Category Expansion Boosts profitability Through 2024.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23
Trump Names Darrell Scott as CDC Tobacco Health Adviser, Citing Tobacco Risks and Harm-Reduction Solutions
Trump Names Darrell Scott as CDC Tobacco Health Adviser, Citing Tobacco Risks and Harm-Reduction Solutions
U.S. President Donald Trump has named Pastor Darrell Scott to serve as an adviser on tobacco health issues on the Centers for Disease Control and Prevention’s Advisory Committee to the Director. Trump said Scott would focus on the burden of tobacco-related disease and help examine ways to protect Americans from dangerous tobacco products while supporting solutions that reduce harm. Scott’s public career has largely centered on faith leadership, community advocacy and politics.
Sep.02
Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
2Firsts reviewed the original federal court complaint filed by Altria subsidiaries Helix Innovations and NJOY on Sept. 2 challenging FDA’s 2021 PMTA rule. The lawsuit questions whether FDA’s review process complies with the Tobacco Control Act’s 180-day timeline, even as the agency moves to accelerate PMTA reviews and issues more marketing orders. Drawing on the complaint, FDA records, government audits and recent court rulings, 2Firsts examines the legal arguments, supporting evidence and potential implications for the U.S. tobacco review system.
Regulations
Sep.03
Canada Considers Easing Pharmacy-Only Nicotine Pouch Sales Rules, Potentially Reopening Convenience Store Channel
Canada Considers Easing Pharmacy-Only Nicotine Pouch Sales Rules, Potentially Reopening Convenience Store Channel
Canada's federal government is considering changes to current restrictions on where nicotine pouches can be sold, potentially allowing authorized products to return to convenience stores and other general retail channels, although no decision has been made. Since 2024, emerging nicotine replacement therapy products such as nicotine pouches have been largely restricted to behind-the-counter pharmacy sales. Health Canada, meanwhile, continues to recall unauthorized and higher-strength nicotine pouches, indicating that the current discussion concerns retail access for authorized products rather than a broad relaxation of nicotine pouch regulation.
Sep.14
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
Turning Point Brands said Executive Chairman David E. Glazek will become CEO on October 1, replacing Graham Purdy, who is stepping down for personal reasons. The company narrowed its 2026 adjusted EBITDA outlook to $70 million-$80 million from $70 million-$90 million while maintaining Modern Oral gross sales guidance of $330 million-$350 million and net sales guidance of $260 million-$270 million. In the second quarter, Modern Oral net sales rose 128% to $68.4 million and accounted for 48% of company-wide net sales. Adjusted EBITDA fell 50% year over year. TPB shares closed about 10% lower on September 21.
Market
Sep.22 by 2Firsts Perspectives
From Nicotine Salts to Cocrystals: China’s Shenzhen Huabao institute explores a more stable form for sustained nicotine release
From Nicotine Salts to Cocrystals: China’s Shenzhen Huabao institute explores a more stable form for sustained nicotine release
China-based Shenzhen Huabao Collaborative Innovation Technology Research Institute Co., Ltd. has filed a patent application for a nicotine-ascorbic acid cocrystal, exploring a new solid-state form of nicotine. The patent proposes applications across e-liquids, heated tobacco sticks, oral tobacco, chewing tobacco and snuff. In nicotine pouch tests disclosed in the filing, cocrystal formulations showed less than a 6% decline in nicotine content after three months of accelerated storage and a release profile combining early-stage release with sustained delivery over 60 minutes. The filing reflects exploration of nicotine forms beyond conventional nicotine base and nicotine salts.
Aug.13